Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma (original) (raw)

Leukemia volume 25, pages 872–874 (2011)Cite this article

Subjects

The insulin-like growth factor (IGF) signaling system is comprised of the IGF ligands (IGF-1 and IGF-2), the cell surface receptors that mediate the biological effects of the IGFs (IGF-1 receptor (IGF-1R), IGF-2 receptor and the insulin receptor), as well as a family of circulating IGF-binding proteins. Insulin-like growth factors 1 and 2 have a critical physiological role in the growth and development of many tissues, and are also implicated in various pathological conditions, particularly in multiple myeloma (MM). Primary cells from patients or MM cell lines are particularly sensitive to IGF-1 and IGF-1R inhibition.1, 2 IGF-1R (CD221) is aberrantly expressed on MM cells in about 75% of the cases and is associated with disease severity.1, 2, 3 It was also shown that IGF-1R (CD221) signaling attenuates responsiveness of MM cells to proapoptotic agents, including dexamethasone, cytotoxics, or proteasome inhibitors.2 IGF-1R is therefore an attractive therapeutic target for MM treatment based on the hypothesis that inhibition of IGF-1R function would result in growth inhibition and apoptosis of tumor cells, particularly in combination with other chemotherapeutic drugs and especially proteasome inhibitors.4

AVE1642 is a humanized version of the murine monoclonal antibody, EM164, raised against the human IGF-1R.5 It has been shown to bind specifically, with a high affinity, to human and monkey IGF-1R, to inhibit IGF-1 binding and receptor activation, and to downregulate the receptor by internalization and degradation. AVE1642 has been able to delay growth and survival of some cancer cells in vitro, human tumor xenografts in nude mice, and to inhibit proliferation and survival of most MM cells (primary cells from patients or MM cell lines).4

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy Jr JD, Barlogie B et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009; 113: 4614–4626.
    Article CAS Google Scholar
  2. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al. Inhibition of IGF-1 receptor tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 221–230.
    Article CAS Google Scholar
  3. Bataille R, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P . CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 2005; 90: 706–707.
    CAS Google Scholar
  4. Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, Amiot M . A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances bortezomib-induced apoptosis in myeloma cells lacking CD45. Br J Cancer 2009; 100: 366–369.
    Article CAS Google Scholar
  5. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63: 5073–5083.
    CAS PubMed Google Scholar
  6. Girard P, Boissel JP . Clockwise hysteresis or proteresis. J Pharmacokinet Biopharm 1989; 17: 401–402.
    Article CAS Google Scholar
  7. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004; 89: 547–551.
    Google Scholar
  8. Descamps G, Wuillème-Toumi S, Trichet V, Venot C, Debussche L, Hercend T et al. CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol 2006; 177: 4218–4223.
    Article CAS Google Scholar
  9. Sprynski AC, Hose D, Kassambara A, Vincent L, Jourdan M, Rossi JF et al. Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia 2010; 24: 1940–1950.
    Article CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. Hematology Department, University Hospital, Nantes, France
    P Moreau
  2. Hematology Department, University Hospital, Torino, Italy
    F Cavallo & M Boccadoro
  3. Hematology Department, University Hospital, Lille, France
    X Leleu & T Facon
  4. Hematology Department, University Hospital, Nancy, France
    C Hulin
  5. Inserm UMR892, Nantes, France
    M Amiot & G Descamps
  6. Sanofi-Aventis, Alfortville, France
    D Mignard
  7. Cancer Center Gauducheau, Saint-Herblain, France
    J L Harousseau

Authors

  1. P Moreau
    You can also search for this author inPubMed Google Scholar
  2. F Cavallo
    You can also search for this author inPubMed Google Scholar
  3. X Leleu
    You can also search for this author inPubMed Google Scholar
  4. C Hulin
    You can also search for this author inPubMed Google Scholar
  5. M Amiot
    You can also search for this author inPubMed Google Scholar
  6. G Descamps
    You can also search for this author inPubMed Google Scholar
  7. T Facon
    You can also search for this author inPubMed Google Scholar
  8. M Boccadoro
    You can also search for this author inPubMed Google Scholar
  9. D Mignard
    You can also search for this author inPubMed Google Scholar
  10. J L Harousseau
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toJ L Harousseau.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

About this article

Cite this article

Moreau, P., Cavallo, F., Leleu, X. et al. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma.Leukemia 25, 872–874 (2011). https://doi.org/10.1038/leu.2011.4

Download citation

This article is cited by